Immutep Limited (IMMP)
Immutep Limited (IMMP) Stock Price, Analysis & Data
| Bid | 0.29 |
| Market Cap | 58.73M |
| Revenue (ttm) | 7.92M |
| Net Income (ttm) | -83.92M |
| Beta | 2.19 |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.99 |
| P/B (ttm) | 0.84 |
| P/S (ttm) | 7.41 |
| Earnings Date | Sep 2, 2026 |
| Ask | 0.5 |
| Volume | 108,115 |
| Avg. Volume (20D) | 454,243 |
| Open | 0.39 |
| Previous Close | 0.39 |
| Day's Range | 0.38 - 0.40 |
| 52-Week Range | 0.29 - 3.53 |
| Analyst | n/a |
| Price Target | 1.5 (275.00%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMMP
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial fo...
Financial Performance
In 2024, Immutep's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -42.72M, an increase of 7.07%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for IMMP stock is "null". The 12-month stock price forecast is 1.5, which is upside of 275% from the latest price.
Stock ForecastsAnalysts project revenue of ... Upgrade
